ReSync Bio Inc.

Established in 2024 by Mihir Trivedi, and based in California, US, ReSync Bio Inc. operates as a biotechnical research optimization solution that offers an integrated platform to streamline preclinical operations. In September 2024, ReSync Bio Inc. raised pre-seed funding from Caffeinated Capital, and Atria Ventures.

   ReSync Bio specializes in providing an integrated platform designed to streamline preclinical operations by coordinating labs, data, and artificial intelligence (AI) models. The core product offering focuses on eliminating operational bottlenecks encountered in biotech research, including the manual management of assays and synthesis requests, data handling through emails and spreadsheets, and disjointed AI model integration. ReSync's solutions enhance decision-making speed by automating workflows and consolidating data from multiple Contract Research Organizations (CROs) and laboratories. Key end users include chemists, biologists, engineers, and management teams across biotech and pharmaceutical sectors, facilitating collaboration in drug discovery and development processes.

  ReSync Bio's revenue model revolves around subscription-based services and partnerships with biotechnology firms, providing them with a comprehensive solution for managing preclinical data and workflows. The company intends to use the September 2024 funding to support the commercialization of its product offerings. Future plans include the development and launch of new features on their platform aimed at improving data integration and automation processes, with a target release date by the end of 2025. Additionally, ReSync Bio aims to expand its presence in European markets by 2026, capitalizing on the increasing demand for automated preclinical solutions.